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ABSTRACT: In a multinational, double-blind, pla-
cebo-controlled trial (NCT00474058), 287 subjects with
Parkinson’s disease (PD) and unsatisfactory early-morn-
ing motor symptom control were randomized 2:1 to
receive rotigotine (2–16 mg/24 hr [n 5 190]) or placebo
(n 5 97). Treatment was titrated to optimal dose over
1–8 weeks with subsequent dose maintenance for 4
weeks. Early-morning motor function and nocturnal
sleep disturbance were assessed as coprimary efﬁcacy
endpoints using the Uniﬁed Parkinson’s Disease Rating
Scale (UPDRS) Part III (Motor Examination) measured in
the early morning prior to any medication intake and
the modiﬁed Parkinson’s Disease Sleep Scale (PDSS-2)
(mean change from baseline to end of maintenance
[EOM], last observation carried forward). At EOM, mean
UPDRS Part III score had decreased by 27.0 points
with rotigotine (from a baseline of 29.6 [standard devia-
tion (SD) 12.3] and by 23.9 points with placebo (base-
line 32.0 [13.3]). Mean PDSS-2 total score had
decreased by 25.9 points with rotigotine (from a base-
line of 19.3 [SD 9.3]) and by 21.9 points with placebo
(baseline 20.5 [10.4]). This represented a signiﬁcantly
greater improvement with rotigotine compared with pla-
cebo on both the UPDRS Part III (treatment difference:
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90 Movement Disorders, Vol. 26, No. 1, 201123.55 [95% conﬁdence interval (CI) 25.37, 21.73]; P 5
0.0002) and PDSS-2 (treatment difference: 24.26 [95%
CI 26.08, 22.45]; P < 0.0001). The most frequently
reported adverse events were nausea (placebo, 9%;
rotigotine, 21%), application site reactions (placebo,
4%; rotigotine, 15%), and dizziness (placebo, 6%; roti-
gotine 10%). Twenty-four-hour transdermal delivery of
rotigotine to PD patients with early-morning motor dys-
function resulted in signiﬁcant beneﬁts in control of
both motor function and nocturnal sleep disturbances.
V C 2010 Movement Disorder Society
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Introduction
Parkinson’s disease (PD) is characterized by motor
symptoms including nocturnal and early morning dys-
tonia and akinesia and is also associated with nonmo-
tor symptoms, such as sleep disorders.
1 These sleep
disorders may be secondary to the patient’s underlying
disease pathology but may, in part, be a consequence
of motor complications and other nonmotor symp-
toms (such as nocturnal pain, insomnia, and vivid
dreams), or medication use. Although the importance
of identifying and treating sleep disorders in PD is
well recognized, few published trials have prospec-
tively studied their management.
2–5
Effective management of nocturnal and early morning
PD symptoms may be achieved with either a long-acting
treatment or by continuous administration of a short-act-
ing treatment.
2,3,6 Rotigotine is a non-ergoline dopamine
agonist that is applied once daily using a transdermal
patch, providing 24 hours of continuous drug delivery,
and is generally well tolerated.
7 Signiﬁcant treatment
beneﬁts of rotigotine have been observed in both early
and advanced PD and include improvements in activities
of daily living and motor symptoms, clinically relevant
reductions in ‘‘off’’ time, and reductions in concomitant
L-dopa dose.
8 Rotigotine’s potential to improve early
morning motor function and sleep-associated problems
in PD was demonstrated recently by two large controlled
studies
9 that showed a reduction in the proportion of
patients awakening in an ‘‘off’’ state.
This study compared the effects of rotigotine and pla-
cebo on early morning motor function and nocturnal
sleep disturbances in subjects with PD. (It should be
noted that while dopamine agonists have a variable
effect on sleep architecture, this was not addressed in
this study.) Effects on nocturnal symptoms such as limb
restlessness, tremor, and cramps and on other nonmo-
tor symptoms such as pain and mood were also investi-
gated. To our knowledge, this is the ﬁrst large,
controlled trial in PD to use sleep outcomes as a copri-
mary outcome measure.
Methods
Design
The RECOVER (Randomized Evaluation of the 24-
hour Coverage: Efﬁcacy of Rotigotine) study
(NCT00474058) was a Phase 3b, double-blind, placebo-
controlled, randomized, parallel-group, two-arm trial
undertaken in 49 centers in 12 countries. Subjects were
recruited between May 2, 2007 and November 17, 2008.
Maximum study duration per subject was 22 weeks, with
a maximum duration of treatment of 12 weeks.
Subjects
Men and women (aged  18 years) with PD (Hoehn
and Yahr Stage I-IV; both ﬂuctuators and nonﬂuctua-
tors) and unsatisfactory control of early morning
motor symptoms as determined by the investigator
(with the latter intended to reﬂect clinical practice),
were eligible for inclusion. PD was deﬁned by the
presence of bradykinesia and at least one of the fol-
lowing: resting tremor, rigidity, or impairment of pos-
tural reﬂexes. Subjects not taking L-dopa were eligible
for study inclusion as were those taking immediate-
release L-dopa provided they had been on a stable
dose for the 28 days prior to baseline (see Supporting
Information text for study exclusion criteria).
Antiemetics without central dopaminergic activity
were permitted to treat nausea and vomiting that
occurred during study drug use. Anticholinergic
agents, monoamine oxidase-B inhibitors, NMDA
antagonists, entacapone, sedatives, hypnotics, selective
serotonin reuptake inhibitors, anxiolytics, and other
CNS medications were permitted if dose was stable
for the 28 days prior to baseline and likely to remain
so for the duration of the study. Controlled-release L-
dopa, other centrally acting dopaminergic agents,
monoamine oxidase-A inhibitors, tolcapone, budipine,
or neuroleptics (except olanzapine, ziprasidone, aripi-
prazole, clozapine, or quetiapine) were prohibited
from 28 days prior to baseline and during the study.
The study was conducted in accordance with Good
Clinical Practice and the Declaration of Helsinki. The
study protocol and amendments were approved by a
national, regional, or Independent Ethics Committee
or Institutional Review Board. All subjects provided
written, informed consent before study participation.
Protocol
Screening took place up to 4 weeks before the base-
line evaluation on Day 1 when subjects were random-
ized 2:1 to receive rotigotine or placebo, stratiﬁed by
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Starting on Day 1 treatment was administered once
daily in the morning using a 24-hour transdermal
patch with identical-looking placebo patches to ensure
blinding. Treatment was titrated to optimal dose (that
at which investigator and subject felt that early morn-
ing motor impairment was adequately controlled) over
1–8 weeks, starting at 2 mg/24 hr and increasing in
weekly increments of 2 mg/24 hr up to a maximum of
16 mg/24 hr. The dose was maintained at the optimal
or maximal dose for a 4-week period (maintenance
period) during which dose reduction (and alteration of
concomitant L-dopa dose, if applicable) was not per-
mitted. During the titration period, rotigotine dose
could be back-titrated once if adverse events (AEs)
occurred that were thought to be the result of exces-
sive dopaminergic stimulation (see Supporting Infor-
mation text). Subjects requiring back-titration
immediately proceeded to the maintenance period.
Clinic visits took place at screening and baseline; ev-
ery 2 weeks during dose titration; start and end of
maintenance; and 30 days after treatment ended. Sub-
jects were hospitalized for 2 nights at baseline (the
ﬁrst an adaptation night) and again at end of mainte-
nance. Subjects who withdrew prematurely were asked
to return to the clinic for a withdrawal visit. Efﬁcacy
assessments were performed after the ﬁrst or second
night of hospitalization depending on the measure (see
Supporting Information text) and at the end of main-
tenance or the withdrawal visit.
Outcome Measures
Coprimary Efﬁcacy Measures
Motor function was assessed in the early morning,
before new patch application or PD medication intake,
using the Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS) Part III (Motor Examination)
10 while in the
practically deﬁned ‘‘off’’ condition. Sleep and nocturnal
disability were assessed using a modiﬁed version of the
original 15-item Parkinson’s Disease Sleep Scale (PDSS-
2; Fig. 1)
11 on which individual items are scored from
0 to 4, with the total score ranging from 0 to 60 where
higher scores indicate greater impairment.
Additional Efﬁcacy Measures
The 15 individual items of the PDSS-2 were examined
as post hoc efﬁcacy measures. Three PDSS-2 domain
scores were also calculated post hoc, by summing indi-
vidual item scores in groups of ﬁve (for a maximum
score of 20): ‘‘disturbed sleep’’ (items 1–3, 8, and 14);
‘‘motor symptoms at night’’ (items 4–6, 12, and 13);
‘‘PD symptoms at night’’ (items 7, 9–11, and 15).
11
Secondary efﬁcacy measures were the Nocturnal
Akinesia, Dystonia and Cramps Score (NADCS),
12
and number of nocturias. Exploratory outcome meas-
ures were the Parkinson’s Disease Non-Motor Symp-
tom scale (NMS)
13; the Beck Depression Inventory
(BDI-II)
14; an 11-point Likert pain scale; the short-
form Parkinson’s Disease Questionnaire (PDQ-8)
15;
and the UPDRS Part II (activities of daily living) and
UPDRS Part IV (complications of therapy) domains
10
(see Supporting Information text).
Safety and Tolerability Measures
Safety and tolerability were assessed throughout the
study and up to 30 days after treatment discontinuation
by monitoring the frequency and severity of AEs (includ-
ing clinically relevant laboratory parameter abnormal-
ities) and any changes in vital signs, physical and
neurological ﬁndings, and ECGs. Emergence of impulse
control disorders was monitored using the modiﬁed Min-
nesota Impulsive Disorder Interview (mMIDI).
16
Statistical Analyses
A sample size of 336 subjects was required to detect
a between-group difference of 3.5 points (standard
deviation [SD] 9.3) in change from baseline UPDRS
Part III score with a power of 90% at the 0.05 signiﬁ-
cance level using a two-sided t test. Unavoidable
changes in the manufacturing process for rotigotine
during the course of the trial led to recruitment being
stopped to avoid enrolled subjects switching to
patches from the new manufacturing process; this
resulted in recruitment of fewer subjects than planned.
Since the power remained >80% at the 0.05 signiﬁ-
cance level, the reduced sample size was deemed to
have no impact on the validity of the trial.
Safety analyses were performed on all randomized sub-
jects who received at least one dose of study drug. Efﬁ-
cacy analyses were performed on the full analysis set
(FAS)—all randomized subjects who received at least
one dose of study drug and had baseline and at least one
post-baseline assessment for both coprimary efﬁcacy
measures (mean change in UPDRS Part III and PDSS-2
scores from baseline to end of maintenance [last observa-
tion carried forward (LOCF); i.e., modiﬁed intent-to-
treat analysis]). The two coprimary endpoints were
tested in a hierarchical sequential fashion, such that if
the testing procedure demonstrated signiﬁcance at the
5% level on UPDRS Part III, the test for the PDSS-2
score was performed (see Supporting Information text).
This enabled evaluation of the motor and non-motor
symptoms of PD without adjustments for multiple com-
parisons. To estimate treatment differences, analyses of
covariance were performed with treatment and pooled
site as factors and baseline score as the covariate.
Results
Subject Disposition
Of 333 subjects screened, 287 were randomized and
246 (86%) completed the study (Fig. 2). The most
TRENKWALDER ET AL.
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consent. All 287 randomized subjects were evaluated
for safety, while 267 subjects were included in the
FAS and evaluated for efﬁcacy.
Baseline Characteristics
Baseline demographic and clinical characteristics,
including UPDRS Part III and PDSS-2 total scores,
were similar between treatment groups (Table 1).
Most subjects (91%) had comorbid conditions at
study entry, the most common of which were hyper-
tension (44%), constipation (15%), depression (14%),
and hypercholesterolemia (14%). Details of concomi-
tant medication use are provided in the Supporting
Information.
Coprimary Efﬁcacy Outcomes
Mean UPDRS Part III scores measured in the early
morning and PDSS-2 total scores showed signiﬁcantly
greater improvement with rotigotine than placebo
from baseline to end of maintenance (least squares
[LS] mean [95% conﬁdence interval (CI)] treatment
differences of  3.55 [ 5.37,  1.73] (P ¼ 0.0002) in
UPDRS Part III and  4.26 [ 6.08,  2.45] (P <
FIG. 1. Modified Parkinson’s Disease Sleep Scale (PDSS-2). V CTrenkwalder and Chaudhuri, 2010.
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ences were similar for L-dopa treated patients ( 3.14
[ 5.22,  1.05] in UPDRS Part III and  4.11 [ 6.18,
 2.05] in PDSS-2) and de novo patients ( 4.84
[ 8.32,  1.36] in UPDRS Part III and  4.54 [ 7.94,
 1.15] in PDSS-2).
Additional Efﬁcacy Outcomes
All three PDSS-2 domain scores showed signiﬁcantly
greater improvement with rotigotine than placebo
from baseline to end of treatment (Fig. 3B). All 15
individual PDSS-2 items except ‘‘distressing hallucina-
tions’’ showed improvement in the rotigotine group;
with signiﬁcant improvements on 10 items, particu-
larly ‘‘difﬁculty falling asleep,’’ ‘‘urge to move arms or
legs,’’ and ‘‘uncomfortable and immobile’’ (Fig. 3B).
Likewise, greater improvement was seen with rotigo-
tine than placebo on the NADCS (LS mean treatment
difference  0.41 [ 0.79,  0.04]; P ¼ 0.030) (Table
2). The number of nocturias in each group changed by
a mean of  0.3 from baseline, and no signiﬁcant dif-
ference was seen between groups (Table 2; LS mean
treatment difference  0.02 [ 0.29, 0.25]; P ¼ 0.88).
The mean NMS total score showed greater improve-
ment with rotigotine than placebo from baseline to
end of treatment (LS mean [95% CI] treatment differ-
ence  6.65 [ 11.99,  1.31]; P ¼ 0.015) (Table 2)
with signiﬁcant differences on the individual scores for
sleep/fatigue and mood/cognition (LS mean treatment
differences of  2.03 [ 3.31,  0.75]; P ¼ 0.002 and
 3.40 [ 5.22,  1.58]; P ¼ 0.0003, respectively). Nu-
merical differences in favor of rotigotine were seen for
attention/memory, gastrointestinal tract, urinary, and
miscellaneous (Table 2).
Greater improvements with rotigotine than placebo
from baseline to end of treatment were seen on the
BDI-II (LS mean treatment difference  2.01 [ 3.55,
 0.47]; P ¼ 0.011); Likert pain scale ( 0.77 [ 1.28,
 0.25]; P ¼ 0.004); PDQ-8 ( 5.74 [ 8.74,  2.75]; P
¼ 0.0002), and UPDRS Part II ( 1.49 [ 2.32,
 0.65]; P ¼ 0.0005) (Table 2). UPDRS Part IV indi-
vidual item scores showed very little change from
baseline to end of treatment in either group (see table
in Supporting Information text), with no signiﬁcant
between-group differences.
Analysis of all outcome measures using observed
cases, and a per protocol analysis of the two copri-
mary outcome measures yielded similar results to
those reported above using LOCF.
Safety and Tolerability Outcomes
The mean duration of drug exposure was 73 days in
the placebo group and 71 days in the rotigotine group.
During the titration phase, 7 (7%) placebo-treated and
40 (16%) rotigotine-treated subjects decreased their
dose by 2 mg/24 hour (or placebo equivalent) due to
tolerability concerns. At the start of maintenance, 67
(35%) rotigotine-treated subjects were taking the maxi-
mal dose of 16 mg/24 hour. Overall, 80% of subjects
were compliant (placebo, 76%; rotigotine 83%).
The most frequently reported AEs during treatment
are shown in Table 3. Two rotigotine-treated subjects
FIG. 2. Subject disposition.
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ject had positive ﬁndings of compulsive sexual behav-
ior on the structured psychiatric interview, which was
not reported as an impulse control disorder AE (this
subject experienced one mild AE of appetite disorder/
decreased appetite). A further 9 subjects (placebo, 2
[2%]; rotigotine, 7 [4%]) had a positive result on at
least one mMIDI module.
Most reported AEs were mild or moderate in inten-
sity (placebo, 96%; rotigotine, 97%). In both treat-
ment groups 6% of subjects discontinued due to any
AE. Five (3%) rotigotine-treated subjects discontinued
due to application/instillation site reactions, none of
which was considered serious. There was no clear
relationship between rotigotine dose and application
site reaction rates. Serious AEs were reported by 5
(5%) placebo-treated subjects and 10 (5%) rotigotine-
treated subjects; only visual hallucination in 1 rotigo-
tine-treated subject led to study withdrawal. Two sub-
jects, both in the placebo group, died during the study
(one committed suicide and the other died of pneumo-
nia aspiration). There were no clinically relevant
changes in vital signs or ECG ﬁndings, and few labo-
ratory test values of clinical relevance.
Discussion
RECOVER is the ﬁrst large-scale, double-blind,
randomized trial to investigate early morning motor
function and sleep as coprimary outcome measures in
PD. In this study, 24-hour transdermal rotigotine
treatment was associated with signiﬁcant beneﬁts ver-
sus placebo in the management of early morning
motor impairment and nocturnal sleep disturbances.
Rotigotine was also associated with improvements in
night-time disabilities (such as limb restlessness, immo-
bility, pain, and cramps), and possibly dopaminergic
nonmotor daytime symptoms (such as fatigue and
mood) as well.
Other dopamine agonists and continuous L-dopa/
DDCI infusion have been used successfully for treating
early morning motor disabilities.
3,17,18 The treatment
difference of 3.55 points on the UPDRS Part III seen
in this 4-week study is consistent with treatment dif-
ferences of 3.91 and 3.82 points on the UPDRS Part
III at the end of 11 weeks of treatment with rotigotine
at doses of 6 mg/24 hr and 8 mg/24 hr in an earlier
dose-ranging study.
19 Likewise, as for rotigotine in the
current study, improvements from baseline of approxi-
mately 7 points on the UPDRS Part III have been
described over periods of 6–24 weeks for cabergoline,
3
L-dopa continuous infusion,
17 and ropinirole con-
trolled release.
18
The clinimetrics of the PDSS are well established
21
and validated in several studies across the world in in-
dependent populations.
22–25 In this study, a modiﬁed
version of the PDSS—the PDSS-2
11—was used; this
modiﬁed scale was developed to better reﬂect treat-
ment effects on nocturnal disabilities and has been
TABLE 1. Baseline demographic and clinical characteristics (safety population
a)
Placebo (n ¼ 96) Rotigotine (n ¼ 191)
Age, mean (SD); range 64.4 (10.6); 37–86 64.8 (9.3); 37–85
Gender, n (%)
Male 61 (64) 123 (64)
Female 35 (36) 68 (36)
BMI, mean (SD) kg/m
2; range 26.6 (4.5); 16–41 26.6 (4.1); 16–43
Race, n (%)
White or Caucasian 85 (89) 177 (93)
Black 1 (1) 2 (1)
Asian 1 (1) 1 (<1)
Other 9 (9) 11 (6)
L-DOPA use, n (%)
No 17 (18) 36 (19)
Yes 79 (82) 155 (81)
Time since ﬁrst diagnosis, mean (SD) years; range 4.9 (4.6); 0–26 4.6 (4.2); 0–23
Disease severity at baseline, UPDRS Part III sum score categories, n (%)
0–9 2 (2) 5 (3)
10–19 12 (13) 38 (20)
20–29 32 (33) 60 (31)
30–39 22 (23) 49 (26)
 40 28 (29) 38 (20)
UPDRS Part III mean (SD) score
b 32.0 (13.3) 29.6 (12.3)
PDSS-2 total mean (SD) score; range
b 20.5 (10.4); 3–49 19.3 (9.3); 1–49
a1 subject randomized to placebo received one dose of rotigotine during dose de-escalation and is counted in the rotigotine group for the safety population.
bRotigotine, n ¼ 190.
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on nocturnal problems. The signiﬁcant improvement
in sleep seen on the PDSS-2 is consistent with results
from a previous prospective open-label trial of rotigo-
tine that used the original PDSS.
20 Sleep disturbances
in PD patients may be caused by a myriad of factors,
including nocturnal motor problems, mood or pain,
and dopaminergic AEs; likewise pain in PD may be
the consequence of other PD symptoms, such as akine-
sia and rigidity. Musculoskeletal problems too might
cause nocturnal pain. Improving nocturnal rigidity
may beneﬁt sleep and pain directly while better sleep
continuity could be expected to improve pain in PD
generally. Hence, in this study, the improvement in
FIG. 3. Mean change from baseline to end of maintenance in (A) UPDRS Part III scores and PDSS-2 total scores and (B) PDSS-2 domain and indi-
vidual item LS mean rotigotine-placebo treatment differences (FAS-LOCF).
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improvement in nocturnal motor symptoms (restless-
ness of arms or legs, urge to move arms or legs, pain-
ful posturing in the morning, and tremor on
awakening). Likewise, improvement on the individual
PDSS-2 item—‘‘painful posturing in the morning’’—
may reﬂect the overall early morning improvement in
akinesia and dystonia observed on the UPDRS Part
III: if akinesia and dystonia improve, pain is relieved
and in turn an overall early morning beneﬁt is seen.
The reported improvements in depressive symptoms
(BDI-II and NMS domain 2) and pain (Likert scale
and PDSS-2 item 10) might also have contributed to
the better sleep outcomes with rotigotine treatment. In
contrast, number of nocturias showed little change
during the study and is unlikely to have had any
impact on sleep outcomes.
Subjective patient assessments in open-label investi-
gations have suggested that long-acting dopaminergic
drugs and formulations may improve sleep dysfunc-
tion in PD patients, possibly through improvement of
sleep maintenance insomnia.
2–4,6,17,26 Indeed, continu-
ous delivery of rotigotine through the night could
explain the reductions in nocturnal PD symptoms, and
might also have counteracted any sleep problems
caused by loss of L-dopa activity. Such observations
have been reported previously with cabergoline and
overnight apomorphine infusion.
4,27
As treatment of the nonmotor symptoms of PD is a
key unmet need in management of the disease as iden-
tiﬁed in recently published guidelines,
28 an additional
outcome in the current study was to investigate the
nonmotor effects of rotigotine examined in pilot stud-
ies.
29 Rotigotine treatment effects in the NMS
domains of sleep/fatigue and mood/cognition support
the ﬁndings from the PDSS-2 and the BDI-II. The
treatment beneﬁt seen in the mood/cognition domain
is most likely due to an improvement in mood, as the
BDI-II showed a signiﬁcant effect of rotigotine on
depressive symptoms.
TABLE 3. Most frequently reported
a treatment-
emergent AEs during overall treatment (safety
population
b)
Adverse event
Number (%) subjects
Placebo
(n ¼ 96)
Rotigotine
(n ¼ 191)
At least 1 treatment-emergent AE
c 54 (56) 137 (72)
Nausea 9 (9) 41 (21)
Application and instillation site reactions 4 (4) 29 (15)
Dizziness 6 (6) 20 (10)
Dyskinesia 4 (4) 15 (8)
Headache 5 (5) 13 (7)
aAt least 5% in either group.
bOne subject randomized to placebo received one dose of rotigotine during
dose de-escalation and is counted in the rotigotine group for the safety
evaluation.
cSubjects could report more than one type of AE.
TABLE 2. Mean change from baseline to end of treatment in the secondary outcomes, NADCS and number of
nocturias, and the exploratory outcomes, NMS total and individual domain scores, BDI-II, Likert pain scale, PDQ-8,
UPDRS Part II (FAS-observed cases)
Mean (SD) baseline score Mean (SD) change
Placebo Rotigotine Placebo Rotigotine
NADCS 2.7 (2.1) (n ¼ 89) 2.9 (2.2) (n ¼ 178)  0.7 (2.1) (n ¼ 89)  1.2 (1.8)
a (n ¼ 178)
Number of nocturias 2.0 (1.8) (n ¼ 89) 1.9 (1.4) (n ¼ 176)  0.3 (1.6) (n ¼ 89)  0.3 (1.3) (n ¼ 176)
NMS total score 41.3 (33.5) (n ¼ 87) 41.1 (34.5) (n ¼ 173)  3.9 (25.5) (n ¼ 86)  10.3 (21.2)
a (n ¼ 172)
Individual NMS domain
Cardiovascular 1.1 (1.9) (n ¼ 89) 1.0 (1.9) (n ¼ 178)  0.2 (1.7) (n ¼ 88) 0.0 (1.9) (n ¼ 178)
Sleep/fatigue 9.1 (8.6) (n ¼ 89) 9.5 (9.4) (n ¼ 176)  1.5 (6.2) (n ¼ 88)  3.7 (6.8)
b (n ¼ 176)
Mood/cognition 7.3 (10.0) (n ¼ 89) 7.1 (9.3) (n ¼ 178) 0.2 (11.1) (n ¼ 88)  3.0 (7.5)
c (n ¼ 178)
Perception/hallucinations 0.4 (1.4) (n ¼ 89) 0.5 (1.7) (n ¼ 178) 0.0 (1.3) (n ¼ 88) 0.1 (2.4) (n ¼ 178)
Attention/memory 3.9 (5.0) (n ¼ 89) 4.5 (6.4) (n ¼ 178) 0.0 (4.8) (n ¼ 88)  0.3 (4.6) (n ¼ 178)
Gastrointestinal tract 4.2 (5.7) (n ¼ 89) 3.6 (4.4) (n ¼ 178) 0.0 (3.9) (n ¼ 88)  0.6 (2.6) (n ¼ 178)
Urinary 6.7 (7.5) (n ¼ 89) 6.6 (7.5) (n ¼ 176)  0.7 (5.0) (n ¼ 88)  1.1 (4.9) (n ¼ 176)
Sexual function 3.9 (6.3) (n ¼ 87) 3.7 (5.7) (n ¼ 177)  0.4 (4.3) (n ¼ 86)  0.2 (4.9) (n ¼ 177)
Miscellaneous 5.1 (5.6) (n ¼ 89) 4.8 (6.4) (n ¼ 178)  1.0 (4.2) (n ¼ 88)  1.3 (3.5) (n ¼ 177)
BDI-II 12.6 (8.8) (n ¼ 89) 12.3 (8.0) (n ¼ 178)  0.8 (7.6) (n ¼ 89)  2.7 (5.7)
a (n ¼ 177)
Likert pain scale 2.6 (2.5) (n ¼ 89) 2.8 (2.4) (n ¼ 178)  0.1 (2.3) (n ¼ 88)  0.9 (2.2)
b (n ¼ 178)
PDQ-8 31.1 (17.0) (n ¼ 89) 30.8 (18.2) (n ¼ 177)  1.2 (13.7) (n ¼ 89)  6.9 (11.9)
c (n ¼ 176)
UPDRS Part II 13.5 (6.3) (n ¼ 89) 12.7 (5.6) (n ¼ 178)  1.3 (3.4) (n ¼ 89)  2.6 (3.6)
c (n ¼ 178)
aP < 0.05;
bP < 0.01;
cP < 0.001 for rotigotine-placebo treatment difference (ANCOVA; Exploratory Analyses).
BDI-II, Beck depression inventory; PDQ-8, short-form Parkinson’s Disease questionnaire; NADCS, Nocturnal Akinesia, Dystonia and Cramps Score; NMS,
Parkinson’s Disease Nonmotor Symptom Assessment Scale; UPDRS, Uniﬁed Parkinson’s Disease Rating Scale; FAS, Full Analysis Set.
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The reported dopaminergic AEs are comparable with
those seen with other nonergoline dopamine ago-
nists.
30 The occurrence of skin reactions showed no
clear dose relationship and is related to use of the
transdermal patch rather than to an allergic reaction
to rotigotine. Few subjects showed emergence of im-
pulsive behavior, with only one rotigotine-treated sub-
ject having a positive result on the structured
psychiatric interview. Two rotigotine-treated subjects
reported a sleep attack.
A signiﬁcant strength of this study is the collection,
under standardized conditions, of controlled data
describing nocturnal disturbances in PD, including dis-
ease-speciﬁc problems such as nocturnal akinesia, rest-
lessness, and nightmares. While this and other trials
that examine early morning akinesia use data based
on the previous night’s sleep in a hospital environ-
ment, our study also used the PDSS-2, which collects
data on the past week of sleep in the patient’s own
home. However, the lack of sleep laboratory data to
measure sleep parameters and their changes objectively
is a limitation. In addition, the inclusion of patients
based on unsatisfactory control of early morning
motor symptoms in the opinion of the investigator
may have led to variation in the study population—
that the majority (82%) of patients were taking L-
dopa at study entry indicates the inclusion of a minor-
ity of de novo patients, which may have produced
some heterogeneity in the observed treatment
response.
Sleep disturbance; nocturnal limb restlessness;
cramps, pain, and immobility; and impairment of
early morning motor function, mood, and health-
related quality of life are common and important
nocturnal, early-morning, and daytime problems for
PD patients. This study demonstrated signiﬁcant
treatment beneﬁts with rotigotine on each of these
outcomes. Indeed, this study is the ﬁrst to conﬁrm
improvements in sleep-related PD problems with a
dopaminergic treatment in a multicenter, double-
blind, randomized, placebo-controlled trial using a
patient-reported outcome as a coprimary outcome
measure. Moreover, it has demonstrated the clinical
beneﬁts of continuous rotigotine delivery, as efﬁcacy
was maintained throughout the night and into the
next morning, signiﬁcantly improving the start of the
new day, one of the most troubling times for PD
patients. However, whether the effects of rotigotine
on the nonmotor symptoms of PD are the result of
its effects on motor symptoms, or whether there are
additional effects of rotigotine which affect nonmotor
qualities such as sleep fragmentation, dreaming, res-
piration and mood, which are unrelated to an
improved motor condition, is still unclear and further
objective study of sleep outcomes in PD patients may
be warranted.
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